The main cause of angioedema is the release of histamine from immune cells, typically triggered by an allergic reaction. This makes allergic angioedema the most common type, with swelling occurring in response to foods like peanuts and shellfish, medications such as antibiotics, insect stings, or latex. But angioedema has a second, less common pathway involving a protein called bradykinin, and understanding which mechanism is behind the swelling changes everything about how it’s treated.
How Allergic Angioedema Works
When your immune system encounters something it has been sensitized to, it launches what’s called a type I hypersensitivity reaction. Immune cells called mast cells and basophils release histamine and other inflammatory chemicals, which force blood vessels to dilate and their walls to become more permeable. Fluid leaks out of the bloodstream and pools in deeper layers of tissue, producing the characteristic puffy, non-pitting swelling of angioedema. The lips, eyelids, tongue, throat, hands, and feet are the most commonly affected areas.
This is the same basic process behind hives, and the two conditions often appear together. In fact, if you develop angioedema alongside an itchy rash, that’s a strong clue that histamine is the driver. Common triggers include peanuts, tree nuts, shellfish, eggs, penicillin and other antibiotics, bee and wasp stings, and natural rubber latex. Swelling usually starts within minutes to an hour of exposure and responds well to antihistamines or epinephrine.
Not all histamine-driven angioedema comes from a classic allergy, though. NSAIDs like ibuprofen and aspirin can cause swelling by disrupting a separate chemical pathway in the body, leading to mast cell activation without an allergic antibody being involved. Direct physical triggers, including cold temperatures and pressure, can also provoke mast cells into releasing histamine.
Bradykinin: The Other Pathway
A second, fundamentally different cause of angioedema involves bradykinin, a powerful molecule that widens blood vessels and increases their permeability. Bradykinin-mediated angioedema looks similar on the outside but behaves differently: it doesn’t cause itching or hives, it develops more slowly (often over hours), it lasts longer (sometimes two to five days), and it does not respond to antihistamines or epinephrine.
Under normal conditions, an enzyme called C1 inhibitor keeps bradykinin production in check by blocking two key enzymes, factor XIIa and plasma kallikrein. When C1 inhibitor is missing or doesn’t work properly, those enzymes run unchecked, kallikrein breaks down a circulating protein to release excessive bradykinin, and fluid pours into tissues.
Drug-Induced Angioedema
One of the most clinically significant causes of bradykinin-mediated angioedema is a class of blood pressure medications called ACE inhibitors. ACE, the enzyme these drugs block to lower blood pressure, also happens to be responsible for breaking down bradykinin. When you take an ACE inhibitor, bradykinin accumulates because the body can’t clear it efficiently.
About 0.2% of people who start an ACE inhibitor develop angioedema while on the medication. That sounds small, but ACE inhibitors are among the most widely prescribed drugs in the world, so the absolute number of cases is substantial. The swelling most often affects the face, lips, and tongue, and it can appear weeks, months, or even years after starting the medication. A related class of diabetes drugs called gliptins (DPP-4 inhibitors) can cause the same problem through a similar mechanism of slowed bradykinin breakdown.
Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic condition that causes recurrent episodes of severe swelling, sometimes without any identifiable trigger. It comes in several forms. In Type I, which is the most common, the body produces too little C1 inhibitor protein. In Type II, it produces normal or even high amounts of C1 inhibitor, but the protein doesn’t function correctly. Both types result from mutations in the C1 inhibitor gene, and the end result is the same: uncontrolled bradykinin production.
A third form, sometimes called HAE with normal C1 inhibitor, was first described in 2000 when researchers identified 10 families in which 36 women, but no men, were affected. All had normal C1 inhibitor levels and activity, ruling out the classic types. Some of these patients carry mutations in the gene for coagulation factor XII. This form tends to cause swelling concentrated in a single area, such as the face or abdomen, and has a somewhat different symptom pattern than classic HAE.
HAE carries serious risks. A review of real-world data covering 3,292 patients found 411 deaths from airway obstruction caused by swelling of the larynx, an average of roughly one death for every 20 patients. Among patients whose family histories were documented, one close relative had died from the same cause for every 7.4 patients studied. Laryngeal edema accounted for between 33% and 56% of all deaths in the studies that tracked cause of death. These numbers reflect populations with varying access to modern treatments, but they underscore why HAE requires a specific management plan.
Idiopathic Angioedema
In some people, no trigger or underlying genetic cause can be found despite thorough testing. This is called idiopathic angioedema, and it appears to fall into two groups. One group responds to antihistamines, suggesting that mast cells and histamine are still the driver even though the specific trigger remains unidentified. A subset of this group may have an autoimmune component, with antibodies similar to those seen in chronic hives provoking mast cell activation. The second group doesn’t respond to antihistamines at all, and the chemical pathway responsible hasn’t been clearly defined.
How Doctors Tell the Difference
Because the two main pathways, histamine and bradykinin, require completely different treatments, identifying the cause matters. A few clinical clues help narrow things down quickly. Angioedema that appears alongside hives and itching, responds to antihistamines, and resolves within 24 to 48 hours is almost certainly histamine-mediated. Angioedema without hives, lasting several days, and not responding to antihistamines points toward bradykinin.
When hereditary angioedema is suspected, the first screening test is a blood level of complement component C4, a protein that is nearly always low in patients with C1 inhibitor deficiency, even between attacks. If C4 is low, the next step is measuring C1 inhibitor activity and protein levels. In Type I HAE, both the level and the activity of C1 inhibitor are reduced. In Type II, the protein level may be normal or elevated, but its activity falls below 50% of the normal range. For the newer form of HAE with normal C1 inhibitor, no reliable lab test currently exists, and diagnosis relies on family history, symptom pattern, and in some cases genetic testing for factor XII mutations.
For allergic angioedema, allergy testing through skin prick tests or specific antibody blood tests can help pinpoint the trigger, whether it’s a particular food, medication, or insect venom. Keeping a detailed log of exposures before episodes is often just as useful as formal testing, especially when the trigger is intermittent or unexpected.
Why the Cause Shapes Treatment
Histamine-mediated angioedema responds to antihistamines, corticosteroids, and in severe allergic reactions, epinephrine. These are widely available and fast-acting. Bradykinin-mediated angioedema, on the other hand, does not respond to any of those medications. Patients with HAE require targeted therapies that either replace C1 inhibitor or block bradykinin production directly. ACE inhibitor-induced angioedema is managed by stopping the medication, after which swelling episodes typically resolve, though it can take weeks for bradykinin levels to normalize.
This distinction is the reason misdiagnosis can be dangerous. A patient with bradykinin-mediated throat swelling treated only with antihistamines and epinephrine may not improve, and the window for effective intervention narrows as the airway swells. Recognizing which pathway is responsible, often from clinical features alone, guides the right treatment from the start.